The content on this site is intended for healthcare professionals only
Dr Javier Cortés talks to ecancer at the 2013 European Cancer Congress about the process of creating biosimilar drugs for approval in Europe.
Dr Cortés explains that biosimilar drugs are genetically similar to already approved drugs but are produced at a much lower cost and can be distributed on a much larger scale.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
